Motley Fool  3 hrs ago  Comment 
Does Novartis think that Google’s ‘smart’ contact lens could become a viable medical device?
SeekingAlpha  Jul 18  Comment 
By BB Research: Novartis (NYSE:NVS) just announced that it is teaming up with Google (NASDAQ:GOOGL) (NASDAQ:GOOG) for bringing Google's smart contact lenses to the healthcare market. Earlier this year, Google unveiled its smart contact lenses for...
TheStreet.com  Jul 17  Comment 
NEW YORK (TheStreet) -- Novartis shares are down -1.2% to $88.93 on Thursday after reporting second quarter earnings of $1.34 that missed Bloomberg analysts estimates by 3 cents.The worlds largest drug maker reported a year over year quarterly...
Motley Fool  Jul 17  Comment 
Novartis's second quarter earnings were ho-hum, but that's not why investors are bullish about the shares
SeekingAlpha  Jul 17  Comment 
Novartis AG (NYSE:NVS) Q2 2014 Results Earnings Conference Call July 17, 2014 08:00 AM ET Executives Joe Jimenez - Chief Executive Officer Harry Kirsch - Chief Financial Officer David Epstein - Head of the Pharma Division Jeff...
newratings.com  Jul 17  Comment 
BRUSSELS (dpa-AFX) - Swiss stocks fell Thursday on news of fresh sanctions on Russia and some disappointing earnings reports. The Swiss Market Index dropped 0.8 percent to 8,548.08, as big banks UBS and Credit Suisse posted...
FiercePharma  Jul 17  Comment 
Take a look at Novartis' second-quarter results for reasons why it engineered that big asset swap-and-sale with GlaxoSmithKline and Eli Lilly. The two units Novartis is unloading, vaccines and animal health, delivered weak sales for the quarter,...
FiercePharma  Jul 17  Comment 
For the past 8 months, Novartis and its partners have been trying to sell the skin-patch maker LTS Lohmann. Two private equity firms appeared ripe for a potential $1.7 billion deal. But that didn't happen. Now, Novartis and the German investment...
Motley Fool  Jul 17  Comment 
Today's top stories in biotech and health care.
Financial Times  Jul 17  Comment 
Swiss pharmaceuticals group says its blockbuster blood pressure drug Diovan now exposed to generic competition in US


Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki